The application of fecal calprotectin in the relapse of inflammatory bowel disease remains uncertain in children and adolescents. We systematically searched the common databases for eligible studies. Judgment of diagnostic accuracy included pooled sensitivity and specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR), and pooled area under the receiver operating characteristic curve. Ultimately, a total of 414 participants from six studies were included. The combined sensitivity, specificity, PLR, and NLR with 95% confidence intervals (CIs) were 0.85 (95% CI = 0.65 to 0.79), 0.71 (95% CI = 0.52 to 0.85), 2.95 (95% CI = 1.71 to 5.09), and 0.21 (95% CI = 0.08 to 0.51), respectively. The area under the summary receiver operating characteristic curve was 0.85, and the DOR was 14.14 (95% CI = 4.46 to 44.80). Our study showed that fecal calprotectin as a biomarker to predict the clinical relapse of inflammatory bowel disease during remission in children and adolescents is effective and worth applying. [Pediatr Ann. 2023;52(9):e357-e362.].

中文翻译：

---

粪便钙卫蛋白预测儿童和青少年炎症性肠病复发：荟萃分析和系统评价。

粪便钙卫蛋白在儿童和青少年炎症性肠病复发中的应用仍不确定。我们系统地搜索了通用数据库以查找符合条件的研究。诊断准确性的判断包括汇总敏感性和特异性、阳性似然比（PLR）、阴性似然比（NLR）、诊断比值比（DOR）和受试者工作特征曲线下的汇总面积。最终，来自六项研究的总共 414 名参与者被纳入。95% 置信区间 (CI) 的组合敏感性、特异性、PLR 和 NLR 分别为 0.85（95% CI = 0.65 至 0.79）、0.71（95% CI = 0.52 至 0.85）、2.95（95% CI = 1.71 至 5.09） ）和 0.21（95% CI = 0.08 至 0.51）。汇总受试者工作特征曲线下面积为 0.85，DOR 为 14.14（95% CI = 4.46 至 44.80）。我们的研究表明，粪便钙卫蛋白作为预测儿童和青少年炎症性肠病缓解期间临床复发的生物标志物是有效的，值得应用。[小儿安。2023；52(9):e357-e362。]。